Table 4.
Incidence per 100,000 person-years at risk and hazard ratios (HRs) for developing incident gout in men and women by different levels of urate at baseline healthcare screening. Results are presented separately for the two time periods; (a) baseline screening until 1998; and (b) from 1998 to end of study period
| SU at baseline, μmol/L | Time period from baseline screening to 1998 | Time period from 1998 to end of study | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Incident gout (n) | Person-years at risk | Inc. (95% CI)* | HR unadjusted (95%CI) | HR age adjusted (95%CI) | Incident gout (n) | Person-years at risk | Inc. (95% CI)* | HR un-adjusted (95%CI) | HR age adjusted (95%CI) | |
| Men | ||||||||||
| ≤ 360 | 8 | 322,368 | 2.5 (1.1–4.9) | 1 | 1 | 447 | 188,039 | 237.7 (216.2–260.8) | 1 | 1 |
| 361–405 | 7 | 63,617 | 11.0 (4.4–22.7) | 4.4 (1.6–12.2) | 4.4 (1.6–12.2) | 227 | 35,336 | 642.4 (561.5–731.67) | 2.7 (2.3–3.2) | 2.7(2.3–3.2) |
| > 405 | 31 | 41,172 | 75.3 (51.2–106.9) | 30.2 (13.9–65.8) | 28.6 (13.1–62.3) | 292 | 19,714 | 1481 (1316–1661) | 6.5 (5.6–7.5) | 6.4 (5.6–7.5) |
| Women | ||||||||||
| ≤ 360 | 1 | 143,968 | 0.7 (0.009–0.4) | n.a. | n.a. | 200 | 137,282 | 145.7 (126.2–167.3) | 1 | 1 |
| 361–405 | 2 | 4026 | 49.7 (5.6–179.3) | n.a. | n.a. | 25 | 3735 | 669.3 (433.1–981.1) | 4.7(3.1–7.2) | 4.4 (2.9–6.7) |
| > 405 | 3 | 2048 | 146.5 (29.5–428) | n.a. | n.a. | 29 | 1589 | 1825 (1222–2621) | 14.0 (9.4–20.6) | 13.1 (8.8–19.4) |
*Per 100,000 person-years at risk